Inside IPEC: Global Initiatives to Expand to Latin America - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside IPEC: Global Initiatives to Expand to Latin America
IPEC extends its reach to Brazil and Argentina in an effort to harmonize excipient best practices.


Pharmaceutical Technology
Volume 34, Issue 12, pp. 50, 54


David R. Schoneker
The International Pharmaceutical Excipients Council (IPEC) Federation was officially formed earlier this year to coordinate IPEC's global activities in the areas of compendial harmonization, excipient guidelines and standards development, and coordination of excipient supply-chain security initiatives with regulatory agencies around the world. The Federation's current membership is made up of IPEC–Americas, IPEC–Europe, IPEC–Japan, and IPEC–China.

IPEC–Americas has also expanded its reach in Latin America through two partnerships. The new relationships will allow the growing pharmaceutical and excipient industries in that region to participate in IPEC activities and to use IPEC guidelines to improve quality and protect patients.

Brazil




In 2009, IPEC–Americas signed a formal partnership agreement with Sindusfarma in Saġ Paulo, Brazil. Sindusfarma is a key pharmaceutical trade association known for publishing various quality and good manufacturing practice (GMP) guidelines for the pharmaceutical industry. The guides are heavily used in the Brazilian pharmaceutical manufacturing sector. However, Sindusfarma has not published any guidelines specifically related to excipients and wanted to help the domestic market gain a better understanding of the types of excipient-control strategies being used in the global market.

As a result of the partnership with IPEC, Sindusfarma now has access to IPEC guidelines such as those on excipient qualification and good distribution practice, and is translating them into Portugese for distribution to the Brazilian regulatory agency, ANVISA, and the local pharmaceutical industry.


IPEC Foundation awards research and innovation
As part of the partnership launch, IPEC–Americas and Sindusfarma cosponsored an Excipient Control Strategies Conference in Saġ Paulo this past August. The event brought together experts and local representatives from IPEC–Americas, the International Pharmaceutical Excipient Auditing (IPEA) organization, and the Brazilian Pharmacopeia, as well as pharmaceutical and excipient manufacturers and excipient distributors to discuss how the use of harmonized guidelines could affect patient safety and the industry in Brazil. Perspectives from the manufacturing and excipient side were provided and discussed. Sessions also addressed third-party audits and the Brazilian Pharmacopeia's plans for handling excipients.

Argentina

IPEC–Americas also entered a partnership agreement with a pharmaceutical professional association in Buenos Aires, Argentina, called Safybi, this past August. Safybi's membership includes pharmacists and pharmaceutical scientists from around the country. The association runs training sessions for the local industry on topics such as GMPs, quality, and formulation science.

As part of the partnership signing ceremony, Safybi hosted an excipient control seminar for their members covering many GMP, quality, and quality-by-design topics. Safybi is now translating the IPEC–PQG Excipient GMP and IPEC good distribution practice guidelines into Spanish. Once completed, these guidelines will be distributed to the industry in Argentina and Safybi will begin work on translating other guidelines.

Looking ahead, IPEC–Americas intends to work with its new partners to to coordinate an annual conference in each country on excipient issues. The organization is also working to set up an IPEC–India in early 2011.

David R. Schoneker is a past chair of IPEC–Americas and director of Global Regulatory Affairs for Colorcon,

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here